Gopal Ramesh, Tucker Susan L, Komaki Ritsuko, Liao Zhongxing, Forster Kenneth M, Stevens Craig, Kelly Jason F, Starkschall George
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):106-13. doi: 10.1016/s0360-3016(03)00094-4.
To determine the relationship between the local radiation dose and the decrease in lung function associated with thoracic irradiation.
Twenty-six patients treated with thoracic irradiation for lung cancer, for whom three-dimensional CT-based dosimetry was used in treatment planning, were evaluated with before and after treatment pulmonary function tests. Six patients were treated with radiotherapy alone (2.15 Gy daily fractions), and 20 patients with concurrent chemotherapy (cisplatin, etoposide) with hyperfractionated (HF) radiation therapy (1.2 Gy in twice-daily fractions). Eleven patients treated with concurrent HF chemoradiation also received the radioprotector amifostine. The normalized decrease in the diffusing capacity for carbon monoxide (DL(CO)) was used as an objective measure of the change in lung function. The dose-volume histogram (DVH) data were used to estimate the local dose-response relationship for loss of DL(CO). In each subvolume of lung, the loss in normalized DL(CO) was assumed to be a sigmoid function of dose, ranging from no loss at low doses to total loss at high doses. The whole-lung decrease in DL(CO) was modeled as the sum of the local declines in DL(CO) over all subvolumes. Nonlinear regression analysis was used to estimate the parameters of the local dose-response function.
The data are most consistent with a pronounced decrease in DL(CO) when the local dose (for radiotherapy alone or HF concurrent chemoradiation) exceeds 13 Gy (95% CI, 11-15 Gy). In patients who received amifostine in addition to HF radiotherapy with concurrent chemotherapy, this stepwise loss of DL(CO) occurred above 36 Gy (95% CI, 25-48 Gy). Grade 2 or higher pulmonary symptoms were associated with a DL(CO) loss of >30% (p = 0.003).
The decrease in pulmonary diffusion capacity correlates with the local dose to irradiated lung. Amifostine significantly reduces the loss in DL(CO). A local dose-loss relationship for normalized DL(CO) can be extracted from DVH data. This relationship allows an estimate of the loss of function associated with a radiation treatment plan. Different plans can thus be compared without resort to an empiric DVH reduction algorithm. The very low (13 Gy) threshold for deterioration of DL(CO) suggests that it is better to treat a little normal lung to a high dose than to treat a lot to a low dose.
确定局部放射剂量与胸部照射相关的肺功能下降之间的关系。
对26例接受胸部照射治疗肺癌的患者进行治疗前和治疗后的肺功能测试评估,这些患者在治疗计划中采用了基于三维CT的剂量测定法。6例患者仅接受放射治疗(每日分次剂量2.15 Gy),20例患者接受同步化疗(顺铂、依托泊苷)联合超分割(HF)放射治疗(每日两次分次剂量1.2 Gy)。11例接受同步HF放化疗的患者还接受了放射保护剂氨磷汀。一氧化碳弥散量(DL(CO))的标准化下降用作肺功能变化的客观指标。剂量体积直方图(DVH)数据用于估计DL(CO)丧失的局部剂量反应关系。在肺的每个子体积中,标准化DL(CO)的丧失被假定为剂量的S形函数,从低剂量时无丧失到高剂量时完全丧失。全肺DL(CO)的下降被建模为所有子体积中DL(CO)局部下降的总和。采用非线性回归分析估计局部剂量反应函数参数。
当局部剂量(仅放射治疗或HF同步放化疗)超过13 Gy(95%CI,11 - 15 Gy)时,数据与DL(CO)明显下降最为一致。在同步化疗联合HF放射治疗时还接受氨磷汀的患者中,DL(CO)的这种逐步丧失发生在36 Gy以上(95%CI,25 - 48 Gy)。2级或更高等级的肺部症状与DL(CO)丧失>30%相关(p = 0.003)。
肺弥散能力的下降与照射肺的局部剂量相关。氨磷汀显著减少DL(CO)的丧失。可以从DVH数据中提取标准化DL(CO)的局部剂量丧失关系。这种关系允许估计与放射治疗计划相关的功能丧失。因此,无需借助经验性的DVH降低算法就可以比较不同的计划。DL(CO)恶化的阈值非常低(13 Gy),这表明将少量正常肺组织照射到高剂量比将大量肺组织照射到低剂量更好。